MyoPowers raises € 4.5M and moves to France

Truffle Capital, Novartis Venture Fund and Gran Plasa have invested into MyoPowers. The funds raised will be used to accelerate the development of ARTUS, MyoPowers’ artificial urinary sphincter, in part by carrying through an important animal study, the first of its kind with this type of device. 

Eric Rambeaux, CEO of MyoPowers, declared: “We’re extremely pleased with the trust shown by our existing investors, Truffle Capital, Novartis Venture Fund and Gran Plasa. Such support is a real recognition of MyoPowers’ innovative approach and the advances made in the development of ARTUS™, our artificial urinary sphincter, which has the potential to solve a major medical problem affecting the health of millions of patients, mostly women, around the world.”

MyoPowers was founded in Lausanne in 2004 by Dr Piergiorgio Tozzi, MD, of the University Hospital of Lausanne (CHUV), Switzerland and Professor Daniel Hayoz of the Cantonal Hospital of Fribourg and the CHUV.. In the press release covering the financing round MyoPowers also announces the relocation: “This new financing round gives MyoPowers the opportunity to become a French company. The relocation of the company’s headquarters to France will allow MyoPowers to immerse itself into the  French environment, in particular in the Alsace region, which is very favorable to innovative startups.”